Company intelligence / Profile preview

Blue Gen Therapeutics Foundation

Sacramento, California, United States

Ownership: Private
Development stage: Other

Overview

BGTF-027 (formerly ADVM-062) is advancing through late-stage preclinical studies for blue cone monochromacy; IND submission and Phase 1 trial protocol preparation are underway at Children’s Hospital Los Angeles. Early funding and licensing achievements are enabling progression toward first-in-human studies. ADVM-082 (for achromatopsia) remains in preclinical development

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAdeno-associated virus-based therapy (AAV-based)
Industry: Biotech

Partnerships

Adverum Biotechnologies (exclusive license for gene therapy programs ADVM-062 & ADVM-082)

Beyond the preview

Go deeper on Blue Gen Therapeutics Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Gen Therapeutics Foundation.

Explore the full profile